The Only Complete Online Marketing Firm
Tuesday, April 19, 2016
High Marks for Novel Neoadjuvant Regimen (CME/CE)
(MedPage Today) -- T-DM1/pertuzumab tops standard therapy in HER2-positive breast cancer
No comments:
Post a Comment
‹
›
Home
View web version
No comments:
Post a Comment